MOUD RESOURCES 2021-2022

echo faqs

DOWNLOAD CASE PRESENTATION FORM

• SESSION 1 - Overview of MOUD Medications

• SESSION 2 - Motivational Interviewing

  • Empowering Change: Motivational Interviewing - SAMHSA resource

  • Screening, Brief Intervention, and Referral to Treatment (SBIRT) - SAMHSA resource

• SESSION 3 - MOUD in Emergency Department

  • References [from slides]

  • Poison Control Center

  • ‘Ohana Coaching - free peer to peer support for people whose family members are living with substance use disorders

• SESSION 4 - MOUD in the Correctional Setting

  • Fentanyl Test Resources

    • National Harm Reduction Coalition

    • Substance Abuse and Mental Health Services Administration (SAMHSA)

    • Legislative Analysis

  • Treatment Court Practitioner Toolkit

  • Justice Community Opioid Innovation Network (JCOIN)

  • Hawaiʻi Opioid Initiative: Prevent Overdose - includes searchable map for naloxone statewide

• SESSION 5 - Psychiatric Co-Morbidities and MOUD

  • Substance Use and Co-Occurring Mental Disorders - NIH Resource

  • Case Presentation from West Hawaiʻi Community Health Center

• SESSION 6 - Withdrawal Syndromes (ETOH, OUD, Benzo)

• SESSION 7 - MOUD: Transition from methadone

  • Clinical Opiate Withdrawal Scale (COWS) - for clinical induction

  • Subjective Opiate Withdrawal Scale (SOWS) - for home induction

• SESSION 8 - Poly substance use and MOUD

  • Fentanyl and Harm Reduction, including information on test strips

• SESSION 9 - Mystery Case

  • Kratom-Induced Liver Injury

• SESSION 10 - Withdrawal/Pain Management

  • Overdose Prevention Services in Hawaiʻi

  • Ten Percent Happier - Mindfulness Resources

  • Mindfulness Coach (VA)

  • “Drug experts on Maui see rise in fentanyl abuse among residents”

• SESSION 11 - Hepatitis C and Opioid Use Disorder

• SESSION 12 - Opioid Overdose Prevention and Naloxone

• SESSION 13 - Hawaiʻi Opioid Initiative Overview

  • Systems Case Study and Updates Presentation

  • Hawaiʻi Opioid Initiative website

  • Fentanyl Information for Hawai’i Island

• SESSION 14 - Infectious Disease and MOUD Literature Review

• SESSION 15 - Liver Disease and Substance Use Disorder

• SESSION 16 - Non-Traditional Buprenorphine Induction

  • Objective Opiate Withdrawal Scale

  • SAMHSA FAQs about New Buprenorphine Guidelines (updated 3/2022)

  • Buprenorphine Microdosing (Randhawa, et al. 2020)

  • Microdosing of Buprenorphine for Induction (Bernese Method)

• SESSION 17 - Pain and Opioid Use Disorder